This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Chronic kidney disease: compounds in this class have renal benefit in people with kidney disease. The benefit appears to be additive to other renal-protective agents, not a replacement for them.
On post #31 — agreed on the reasoning, with one qualification.
Interactions between comorbidities: diabetes and kidney disease together change the risk calculation for hypoglycemia and for medication clearance. They are not independent variables.
Multiple comorbidities: a person with diabetes, kidney disease, and cardiovascular disease is outside the studied populations in most trials. Extrapolating to that person requires reasoning from the individual component trials and mechanisms.
Two things before anyone answers the substance.
First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.
Obstructive sleep apnoea: SURMOUNT-OSA used an objective endpoint, the apnoea-hypopnoea index. Reduction was substantial. Whether the benefit is weight loss or a direct drug effect is not resolved by the trial.
Type 2 diabetes: the population with the largest evidence base for these compounds. The SURPASS and SUSTAIN programmes established glycaemic benefit. The renal and cardiovascular benefit evidence is separate from the glycaemic benefit evidence.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Hepatic steatosis: what the MASH trial evidence supports — one year on
On the subject in the title: Hepatic steatosis: what the MASH trial evidence supports — one year on Working notes rather than a conclusion. General question, not a request for advice about my own care — I…
|
2 | 4.1k | 6mo | |
|
Heart failure with preserved ejection fraction: symptom endpoints
Heart failure with preserved ejection fraction: symptom endpoints — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a person. The published…
|
+19 | 23 | 311 | 12d |
|
Hepatic steatosis: what the MASH trial evidence supports
Hepatic steatosis: what the MASH trial evidence supports — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a person. The published trials in…
|
+77 | 83 | 950 | 13mo |
|
Type 2 diabetes and the largest part of the evidence base — does this still hold?
Type 2 diabetes and the largest part of the evidence base — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Asking about a population rather…
|
+17 | 22 | 4.5k | 1d |
|
Hypertension improvement and when medication needs revisiting — a second dataset
Posting this under the heading it deserves: Hypertension improvement and when medication needs revisiting — a second dataset Everything below is what sits behind that. General question, not a request for…
|
+126 | 133 | 22k | 21mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Cardiovascular risk: reading the outcome trials as a set
Cardiovascular risk: reading the outcome trials as a set Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The published…
|
4 | 12k | 5mo | |
|
People with a low starting BMI: where the evidence stops
Posting this under the heading it deserves: People with a low starting BMI: where the evidence stops Everything below is what sits behind that. Asking about a population rather than about a person. The…
|
+23 | 27 | 5.8k | 19mo |
|
Type 2 diabetes and the largest part of the evidence base — does this still hold?
Type 2 diabetes and the largest part of the evidence base — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Asking about a population rather…
|
+18 | 25 | 1.7k | 22mo |
|
Renal impairment: what the labelling says about dose
On the subject in the title: Renal impairment: what the labelling says about dose Working notes rather than a conclusion. General question, not a request for advice about my own care — I know the difference…
|
4 | 8.9k | 19mo | |
|
Hepatic steatosis: what the MASH trial evidence supports — one year on
On the subject in the title: Hepatic steatosis: what the MASH trial evidence supports — one year on Working notes rather than a conclusion. General question, not a request for advice about my own care — I…
|
2 | 4.1k | 6mo |